Prognostic factors for transformation in asymptomatic immunoglobulin M monoclonal gammopathies

Clinical Lymphoma

Volumn 5, Issue 4, 2005, Pages 265-269

  Morra, Enrica ^a   Cesana, Clara ^b   Klersy, Catherine ^c   Barbarano, Luciana ^a   Miqueleiz, Sara ^a   Varettoni, Marzia ^c   Lucchesini, Camilla ^a   Ricci, Francesca ^a   Lazzarino, Mario ^d  

^a Niguarda Ca' Granada Hospital   (Italy)

^b Servizio di Fisiopatologia Respiratoria G Campari   (Italy)

^c FONDAZIONE IRCCS POLICLINICO SAN MATTEO   (Italy)

^d UNIVERSITY OF PAVIA   (Italy)

Author keywords

Bence Jones proteinuria; Bone marrow histopathology; Monoclonal gammopathy of undetermined significance; Symptomatic lymphoproliferative disease

Indexed keywords

BENCE JONES PROTEIN; IMMUNOGLOBULIN M;

ADULT; AGED; AMYLOIDOSIS; ARTICLE; BONE MARROW BIOPSY; CONFIDENCE INTERVAL; CORRELATION ANALYSIS; DISEASE ASSOCIATION; DISEASE COURSE; ERYTHROCYTE SEDIMENTATION RATE; FEMALE; HEMOGLOBIN DETERMINATION; HIGH RISK PATIENT; HISTOPATHOLOGY; HUMAN; IMMUNOGLOBULIN STRUCTURE; IMMUNOPHENOTYPING; KAPLAN MEIER METHOD; LYMPHOCYTIC INFILTRATION; LYMPHOCYTOSIS; LYMPHOPROLIFERATIVE DISEASE; MAJOR CLINICAL STUDY; MALE; MALIGNANT TRANSFORMATION; MONOCLONAL IMMUNOGLOBULINEMIA; MULTIPLE MYELOMA; MULTIVARIATE ANALYSIS; NONHODGKIN LYMPHOMA; PARTICLE SIZE; PROBABILITY; PROGNOSIS; PROTEINURIA; RISK ASSESSMENT; RISK FACTOR; STATISTICAL SIGNIFICANCE; SURVIVAL RATE; SURVIVAL TIME; WALDENSTROEM MACROGLOBULINEMIA;

EID: 18144373482     PISSN: 15269655     EISSN: None     Source Type: Journal    
DOI: 10.3816/CLM.2005.n.013     Document Type: Article

References (20)

1. Gandara DR, Mackenzie MR. Differential diagnosis of monoclonal gammopathy. Med Clin North Am 1988; 72:1155-1167.
2. Dhodapkar MV, Jacobson JL, Gertz MA, et al. Prognostic factors and response to fludarabine therapy in patients with Waldenström macroglobulinemia: results of United States intergroup trial (Southwest Oncology Group S9003). Blood 2001; 98:41-48.
3. García-Sanz R, Montoto S, Torrequebrada A, et al. Waldenström macroglobulinemia: presenting features and outcome in a series with 217 cases. Br J Haematol 2001; 115:575-582.
4. Facon T, Brouillard M, Duhamel A, et al. Prognostic factors in Waldenström's macroglobulinemia: a report of 167 cases. J Clin Oncol 1993; 11:1553-1558.
5. Morel P, Monconduit M, Jacomy D, et al. Prognostic factors in Waldenström macroglobulinemia: a report on 232 patients with the description of a new scoring system and its validation on 253 other patients. Blood 2000; 96:852-858.
6. Gertz MA, Fonseca R, Rajkumar SV. Waldenström's macroglobulinemia. Oncologist 2000; 5:63-67.
7. Owen RG, Johnson SA, Morgan GJ. Waldenström's macroglobulinemia: laboratory diagnosis and treatment. Hematol Oncol 2000; 18:41-49.
8. Owen RG, Barrans SL, Richards SJ, et al. Waldenström macroglobulinemia. Development of diagnostic criteria and identification of prognostic factors. Am J Clin Pathol 2001; 116:420-428.
9. Dimopoulos MA, Panayiotidis P, Maulopoulos LA, et al. Waldenström's macroglobulinemia: clinical features, complications, and management. J Clin Oncol 2OOO; 18:214-226.
10. Kyle RA, Garton JP. The spectrum of IgM monoclonal gammopathy in 430 cases. Mayo Clin Proc 1987; 62:719-731.
11. Owen RG, Treon SP, Al-Katib A, et al. Clinicopathological definition of Waldenström's macroglobulinemia: Consensus Panel recommendations from the Second International Workshop on Waldenström's macroglobulinemia. Semin Onco 2003; 30:110-115.
12. Cesana C, Klersy C, Barbarano L, et al. Prognostic factors for malignant transformation in monoclonal gammopathy of undetermined significance and smoldering multiple myeloma. J Clin Oncol 2002; 20:1625-1634.
13. Van de Poel MHW, Coebergh JWW, Hillen HFP. Malignant transformation of monoclonal gammopathy of undetermined significance among out-patients of a community hospital of southeastern Netherlands. Br J Haematol 1995; 91:121-125.
14. Bartl R, Frisch B, Mahl G, et al. Bone marrow histology in Waldenström's macroglobulinaemia. Clinical relevance of subtype recognition. Scand J Haematol 1983; 31:359-375.
15. Kyrtsonis MC, Vassilakopoulos TP, Angelopoulou MK, et al. Waldenström's macroglobulinemia: clinical course and prognostic factors in 60 patients. Ann Hematol 2001; 80:722-727.
16. Harris NL, Jaffe ES, Stein H, et al. A revised European-American classification of lymphoid neoplasms: a proposal from the International Lymphoma Study Group. Blood 1994; 84:1361-1392.
17. Bennett JM, Catovsky D, Daniel MT, et al. Proposals for the classification of chronic (mature) B and T lymphoid leukaemias. French-American-British (FAB) Cooperative Group. J Clin Pathol 1989; 42:567-584.
18. Pangalis GA, Angelopoulou MK, Vassilakopoulos TP, et al. B-chronic lymphocytic leukemia, small lymphocytic lymphoma, and lymphoplasmacytic lymphoma, including Waldenström's macroglobulinemia: a clinical, morphologic, and biologic spectrum of similar disorders. Semin Hematol 1999; 36:104-114.
19. Alexanian R, Weber D, Delasalle K, et al. Asymptomatic Waldenström's macroglobulinemia. Semin Oncol 2003; 30:206-210.
20. Kyle RA, Therneau TM, Rajkumar SV, et al. Long-term follow-up of IgM monoclonal gammopathy of undetermined significance. Blood 2003; 102:3759-3764.